Value of Analysing Under-utilised Leftover Tissue (VauLT)
VauLT
1 other identifier
observational
800
1 country
1
Brief Summary
Intratumour heterogeneity is well recognized in multiple cancer types and ultimately leads to therapeutic resistance. It also limits the ability of small samples to represent the whole tumour, having implications for diagnosis, molecular analysis and understanding of the tumour immune microenvironment. By blending- 'homogenizing'- leftover tumour tissue in excess of that required for diagnosistic purposes, one may create a more representative sample for analysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 10, 2018
CompletedFirst Submitted
Initial submission to the registry
January 24, 2019
CompletedFirst Posted
Study publicly available on registry
February 6, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
May 18, 2025
May 1, 2025
10 years
January 24, 2019
May 14, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
The percentage of cases from surgical lists with tumour remains greater than 1g across 8 tumour groups
Surgical lists will be generated providing cases of all surgeries containing excess tumour tissue. The tissue will be dissected and weighed to determine if tumour tissue available is greater than 1g
24 Months
Secondary Outcomes (3)
Median time (in minutes) required for dissection of the leftover surgical tissue into tumour, tumour-adjacent and normal tissue
24 Months
Median time (in minutes) required for the blending (actual homogenization) of each tissue type
24 Months
Difference in molecular profile between the diagnostic block and the homogenized sample. This will be measured by next generation sequencing techniques across the 8 primary tumour types
24 Months
Interventions
Leftover surgical tissue homogenization
Eligibility Criteria
Leftover formalin-fixed tissue from cancer surgery
You may qualify if:
- Leftover formalin-fixed tissue (ie that would be otherwise discarded by histopathology) from cancer surgery.
- Tissues for Research consent has been provided.
- Patient age \>18yo.
- Minimum of 1 gram of residual tumour remaining in leftover surgical tissue
- Minimum of 1 gram of normal tissue present.
You may not qualify if:
- Advanced Practitioner in histological dissection deems tumour sample to be inadequate.
- Leftover surgical tumour tissue greater than 20kg.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Royal Marsden NHS Foundation Trustlead
- Ventana Medical Systemscollaborator
Study Sites (1)
Royal Marsden Hospital NHS Foundation Trust
London, SW3 6JJ, United Kingdom
Biospecimen
The investigators will be collecting leftover formalin-fixed surgical tissue homogenate and FFPE tumour blocks
MeSH Terms
Conditions
Study Officials
- STUDY CHAIR
Samra Turajlic
Royal Marsden NHS Foundation Trust
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 24, 2019
First Posted
February 6, 2019
Study Start
September 10, 2018
Primary Completion (Estimated)
August 31, 2028
Study Completion (Estimated)
December 31, 2028
Last Updated
May 18, 2025
Record last verified: 2025-05